Published in Monoclonal Antibodies Weekly, May 17th, 2000
"Increased gene copy number of erbB-2 and overexpression of the proto-oncogene product erbB-2 (HER-2/p185) has been reported in 20%-30% of human breast cancers and is associated with decreased time to relapse, increased metastatic properties, and ultimately a decrease in survival time," said R.A. Newberry and colleagues from McMaster University, Canada. "Monoclonal antibodies (MAbs) directed against erbB-2 inhibit the growth of transformed cells that express...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Monoclonal Antibodies Weekly